Jaypirca is a new kind* of inhibitor for relapsed MCL
*Jaypirca is the only FDA-approved noncovalent BTK inhibitor.
Jaypirca is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) that has come back or did not respond following two prior cancer treatments, including a BTK inhibitor.
Jaypirca is an oral medication you can take at home. For more information on dosing and administration, click here.
You may have taken BTK inhibitors before. Cancer drugs called BTK inhibitors can stop, or inhibit, cancer cells from surviving and multiplying, which slows the spread of MCL.
With Jaypirca, you can continue to treat your MCL and focus on what matters most. When your MCL comes back or does not respond while taking a BTK inhibitor, or if you were unable to tolerate a previous BTK inhibitor due to side effects, Jaypirca could be an option for you.
SELECT SAFETY INFORMATION
Warnings - Jaypirca may cause serious side effects, including:
Bleeding problems (hemorrhage). Bleeding problems can happen during treatment with Jaypirca. They can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your doctor if you have any signs or symptoms of bleeding, including:
- blood in your stools or black stools (looks like tar)
- pink or brown urine
- unexpected bleeding, or bleeding that is severe or you cannot control
- vomit blood or vomit blood that looks like coffee grinds
- cough up blood or blood clots
- increased bruising
- changes in your speech
- headache that lasts a long time
Ask your doctor if Jaypirca could be right for you
Jaypirca has a distinct way of working compared to other BTK inhibitors
Jaypirca works differently than other BTK inhibitors you may have taken before. It was developed to work after you have taken another BTK inhibitor. There are no completed studies comparing Jaypirca and other BTK inhibitors.